BRIEF-Tonix Pharmaceuticals Announces Submission Of The TNX-102 Sl New Drug Application (NDA) For Fibromyalgia To The U.S. Food And Drug Administration (FDA)

Reuters
16 Oct 2024

Oct 16 (Reuters) - Tonix Pharmaceuticals Holding Corp

:

* TONIX PHARMACEUTICALS ANNOUNCES SUBMISSION OF THE TNX-102 SL NEW DRUG APPLICATION (NDA) FOR FIBROMYALGIA TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)

* TONIX PHARMACEUTICALS HOLDING CORP - FDA DECISION ON TNX-102 SL EXPECTED IN 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10